• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

The Global Burden of Asthma Prevalence on Specific Subgroups

News
Article

The prevalence of eosinophilic asthma and severe asthma phenotypes was high in many countries, according to one study.

A global study on the prevalence of asthma and its impact on specific subgroups found countries with higher air quality, income status, and health care access and quality reported higher asthma rates compared with low- and middle-income countries (LMIC). These findings suggest a poor understanding of asthma’s epidemiology, which may result in low diagnosis and underreporting among LMICs, according to the study.

This research was published in the Journal of Asthma and Allergy.

Patient suffering from allergic asthma symptoms. Pneumonia treatment. Obstructive pulmonary disease, chronic bronchitis, emphysema concept | Visual Generation - stock.adobe.com

Patient suffering from allergic asthma symptoms. Pneumonia treatment. Obstructive pulmonary disease, chronic bronchitis, emphysema concept | Visual Generation - stock.adobe.com

“The goal of this study was to determine the global prevalence of asthma and its aforementioned phenotypes (EA [eosinophilic asthma] and SA [severe asthma]), along with the prevalence of asthma with AR [allergic rhinitis] or NPs [nasal polyps], and to explore underlying drivers for the observed patterns,” the researchers of the study wrote. “To do this, we examined the scientific literature for studies reporting asthma and subgroup prevalence, and compared our results to country-specific qualities like economic status and air quality.”

Because asthma commonly presents as other respiratory symptoms such as coughing, wheezing, shortness of breath, and chest tightness, heterogeneous real-world practices often lack resources or medical training, which can complicate the diagnostic process and lead to underreporting and difficulty interpreting prevalence estimates, especially in LMICs.

In this study, researchers aimed to report prevalence estimates for asthma and key clinical subgroups: nasal polyps, allergic rhinitis, severe asthma, and eosinophilic asthma. Data were extracted from the Global Burden of Disease, Injuries, and Risk Factors Study 2019 and a literature review through PubMed in October 2021.

Asthma prevalence values were obtained from 69 countries, based on estimates from 405 sources from epidemiological reports and scientific literature. The targeted literature review included 9 studies with prevalence estimates for the different subgroups, with additional sources included where available per country/disease category. The literature included real-world evidence studies, along with some reviews, to form the base of the pearl-growing technique to find additional sources of the same level of relevance and authority.

Additionally, a qualitative analysis was conducted to include country-specific factors affecting global prevalence distributions. Asthma prevalence values were aggregated according to 2020 Air Quality Index (AQI) values, 2022 World Bank economic status, and 2017 Institute for Health Metrics and Evaluation Healthcare Access and Quality (HAQ) values.

A total of 162 publications were included in the study, with asthma prevalence values ranging across continents from 3.44% (Asia), 3.67% (Africa), 4.90% (South America), 5.69% (Europe), 8.29% (North America), to 8.33% (Oceana).

The global asthma prevalence according to subgroups included:

  • Severe Asthma, 26.7%
  • Eosinophilic asthma, 0.99%
  • Asthma rhinitis, 48.95%
  • Nasal polyps, 7% to 25.4%

Furthermore, countries with higher air quality, income status, and health care access and quality reported a higher asthma prevalence. For instance, the United States had the highest asthma prevalence (11.25%) and had good AQI (9.6), while Bangladesh reported the lowest asthma prevalence (1.43%) and had poor AQI (77.1). The researchers explained these results may be attributed to fine-scale geographical variations in air quality that are not captured by AQI, as well as the presence of household pollution that is extremely common in many countries.

However, the researchers also acknowledged that even in countries with higher HAQ, clinicians may still struggle to diagnose and provide care for patients with asthma.

The study was limited mainly due to the possible lack of reliable and accurate data, especially among clinical subgroups of asthma in LMICs. Yet, the findings support existing efforts to standardize health care practices, increase access to care, and improve reporting practices to reduce the global burden of asthma, according to the study.

“This study brought together information on the reported prevalence of asthma and asthma subgroups, as well as country-specific variables of AQI, HAQ, and economic status,” the researchers wrote. “The targeted searches adhered to the methodical pearl-growing technique to identify the most relevant sources of reported asthma subgroup prevalence.”

Reference

Rabe AP, Loke WJ, Gurjar K, Brackley A, Lucero-Prisno III DE. Global burden of asthma, and its impact on specific subgroups: Nasal polyps, allergic rhinitis, severe asthma, eosinophilic asthma. Journal of Asthma and Allergy. 2023;Volume 16:1097-1113. doi:10.2147/jaa.s418145

Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Joseph Zabinksi, PhD, MEM, vice president, head of commercial strategy and AI, OM1
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.